Loading…
Citius Oncology, Inc. is projected to rise to $0.9078 by 2027, a +2% move from its current price of $0.8889. CTOR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8507 | $0.8885 | $0.9281 | -0.04% |
| May 30 | $0.8351 | $0.8882 | $0.9446 | -0.08% |
| May 31 | $0.8233 | $0.8878 | $0.9573 | -0.12% |
| Jun 1 | $0.8134 | $0.8874 | $0.9682 | -0.17% |
| Jun 2 | $0.8048 | $0.8871 | $0.9778 | -0.21% |
| Jun 3 | $0.797 | $0.8867 | $0.9865 | -0.25% |
| Jun 4 | $0.7899 | $0.8863 | $0.9946 | -0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7899 | $0.8863 | $0.9946 | -0.29% |
| Week 2 | $0.7509 | $0.8838 | $1.04 | -0.58% |
| Week 3 | $0.7218 | $0.8812 | $1.08 | -0.87% |
| Week 4 | $0.6978 | $0.8786 | $1.11 | -1.15% |
| Week 5 | $0.6771 | $0.8761 | $1.13 | -1.44% |
| Week 6 | $0.6588 | $0.8736 | $1.16 | -1.73% |
| Week 7 | $0.6422 | $0.871 | $1.18 | -2.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Citius Oncology, Inc. is a healthcare company focused on the development and commercialization of innovative targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
The company is headquartered in Cranford, New Jersey, and Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
CTOR trades at $0.8399 per share, with a market cap of $78.09M and a rank of 4380.
The near-term forecast places the 2026 average price at $0.8399, with a min of $0.493 and a max of $1.02.
Longer-term forecasts show higher upside, with average prices rising to $1.08 in 2028, $1.26 in 2029, $1.24 in 2030, and continuing to $1.78 in 2035.
By 2050, the forecast projects an average price of $3.65, with a potential max of $8.39 and a maximum implied ROI of 334.6%, indicating substantial upside, subject to risk.
A major floor 44.5% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 11.0% above — a clean break opens room to run.
A major ceiling 37.2% above — clearing it would confirm fresh momentum.
Key CTOR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTOR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.8488 | Buy | $0.8646 | Buy |
| MA 10 | $0.8835 | Buy | $0.8718 | Buy |
| MA 20 | $0.8961 | Sell | $0.8749 | Buy |
| MA 50 | $0.7933 | Buy | $0.8783 | Buy |
| MA 100 | $0.9419 | Sell | $0.9714 | Sell |
| MA 200 | $1.26 | Sell | $1.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.44 | Neutral |
| Stoch RSI (14) | 43.64 | Neutral |
| CCI (20) | -11.10 | Neutral |
| Williams %R (14) | -60.87 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -1.98 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 39.13 | Neutral |
| TRIX (15) | 0.31 | Buy |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 39.25 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 0.85 | Buy |
| ADX (14) | 15.38 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is NEUTRAL.
RSI(14) sits at 50, with the 50-day simple moving average at $0.7907 and the 200-day SMA at $1.27.
Near-term support is $0.68 and resistance is $0.987, with the 30-day range between $0.6228 and $1.13.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.493 | $0.8889 | $1.09 | 0% | Neutral | |
| $0.6784 | $0.9078 | $1.31 | +2% | Neutral | |
| $0.8223 | $1.15 | $1.75 | +30% | Bullish | |
| $0.9342 | $1.36 | $2.15 | +53% | Bullish | |
| $0.8905 | $1.35 | $2.20 | +51% | Bullish | |
| $0.7883 | $1.23 | $2.07 | +38% | Bullish | |
| $0.8427 | $1.36 | $2.35 | +53% | Bullish | |
| $0.7952 | $1.32 | $2.34 | +49% | Bullish | |
| $0.8458 | $1.45 | $2.62 | +63% | Bullish | |
| $1.12 | $1.97 | $3.63 | +121% | Bullish | |
| $1.05 | $2.11 | $4.24 | +138% | Bullish | |
| $1.86 | $4.14 | $9.35 | +365% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.493 | $0.8889 | $1.05 | +0.00% |
| June 2026 | $0.7147 | $0.8503 | $1.04 | -4.35% |
| July 2026 | $0.7097 | $0.8559 | $1.07 | +0.67% |
| August 2026 | $0.7355 | $0.8967 | $1.14 | +4.76% |
| September 2026 | $0.7063 | $0.8687 | $1.12 | -3.12% |
| October 2026 | $0.6544 | $0.8115 | $1.06 | -6.59% |
| November 2026 | $0.6539 | $0.8168 | $1.08 | +0.66% |
| December 2026 | $0.6521 | $0.8203 | $1.09 | +0.42% |
Click any year to see its month-by-month CTOR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CTOR price prediction for 2026 points to an average of $0.8889 (low $0.493, high $1.09) — a potential gain of 0% on today's $0.8889. A consolidation phase looks the most probable path here.
In 2027, CTOR is projected to trade between $0.6784 and $1.31, averaging $0.9078 — a potential gain of +2% from today's $0.8889. That is up +2% on the projected 2026 average. Price action looks broadly range-bound.
Citius Oncology, Inc.'s 2028 outlook centres on $1.15, within a $0.8223 to $1.75 range. That is up +27% on the projected 2027 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CTOR could reach as high as $2.15, with a base case around $1.36 and support toward $0.9342 — roughly +53% from $0.8889. Momentum favours further upside here.
Expect CTOR to range from $0.8905 to $2.20 through 2030. The $1.35 average target implies a +51% move from current prices. That is -1% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The CTOR price prediction for 2031 points to an average of $1.23 (low $0.7883, high $2.07) — a potential gain of +38% on today's $0.8889. Momentum favours further upside here.
In 2032, CTOR is projected to trade between $0.8427 and $2.35, averaging $1.36 — a potential gain of +53% from today's $0.8889. That is up +10% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Citius Oncology, Inc.'s 2033 outlook centres on $1.32, within a $0.7952 to $2.34 range. That is -3% versus the projected 2032 average. That marks a +49% change versus current levels. Momentum favours further upside here.
By 2034, CTOR could reach as high as $2.62, with a base case around $1.45 and support toward $0.8458 — roughly +63% from $0.8889. Buyers look set to stay in control over this stretch.
Expect CTOR to range from $1.12 to $3.63 through 2035. The $1.97 average target implies a +121% move from current prices. That is up +36% on the projected 2034 average. Momentum favours further upside here.
The CTOR price prediction for 2040 points to an average of $2.11 (low $1.05, high $4.24) — a potential gain of +138% on today's $0.8889. Buyers look set to stay in control over this stretch.
In 2050, CTOR is projected to trade between $1.86 and $9.35, averaging $4.14 — a potential gain of +365% from today's $0.8889. That is up +96% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CTOR today (≈ 1,124.985938 CTOR) could be worth
$4,653.26
+$3,653.26 (+365%) by 2050 · US Dollar
Based on the average projected CTOR price of $4.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTORwould be worth at today's price.
$1,000 invested in CTOR on May 27, 2025 (≈ 1,123.595524 CTOR) would be worth
$998.76
-$1.24 (-0.1%) today · 1.00× · US Dollar
Based on a CTOR entry price of $0.89 vs. today's $0.8889.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.826 | $1,076.15 | +7.6% |
| 1 month ago | $0.874 | $1,017.05 | +1.7% |
| 3 months ago | $1.09 | $815.5 | -18.4% |
| 6 months ago | $1.37 | $648.83 | -35.1% |
| 1 year ago | $0.89 | $998.76 | -0.1% |
| All time (3.5y) ago | $10.09 | $88.1 | -91.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTOR forecast.
Our base-case forecast reaches $1.80 around 2035.
Implied market cap at $1.80: $167.37M
The multi-year forecast shows a bullish path beginning in the later years. The 2028 average price is $1.08 with a 28.3% upside, followed by the 2029 average of $1.26 with a 49.6% ROI and the 2030 average of $1.24 with a 47.2% ROI.
Forecasts extend through 2035, 2040, and 2050 with rising averages and strong ROIs: 2035 average $1.78 with 111.5% ROI; 2040 average $1.89 with 125.3% ROI; 2050 average $3.65 with 334.6% ROI.
Max prices also show upside potential: 2035 max $3.33, 2040 max $3.87, and 2050 max $8.39.
These figures are estimates and not guarantees.
Tap a question to reveal the answer.
Min $0.8072, avg $1.24, max $2.05; ROI 47.2%; sentiment BULLISH.
Forecasts show bullish sentiment in multiple years with high upside by 2050 (avg $3.65, max $8.39; ROI 334.6%), though these are estimates and not guarantees.
Yes. The forecast max prices include $3.33 in 2035 and $3.87 in 2040, and $8.39 in 2050.
Min $0.493, avg $0.8399, max $1.02; sentiment NEUTRAL.
Min $1.64, avg $3.65, max $8.39; ROI 334.6%; sentiment BULLISH.
Citius Oncology, Inc. Community Discussion
0Share your Citius Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.